Rosiglitazone decreases postprandial production of acylation stimulating protein in type 2 diabetics
<p>Abstract</p> <p>Background</p> <p>We evaluated plasma ASP and its precursor C3 in type 2 diabetic men with/without rosiglitazone (ROSI) treatment compared to healthy non-obese men. We tested (1) whether plasma ASP or C3 are altered postprandially in subcutaneous adip...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2007-05-01
|
| Series: | Nutrition & Metabolism |
| Online Access: | http://www.nutritionandmetabolism.com/content/4/1/11 |